Business Wire

NY-CONCIERGE-AUCTIONS

7.6.2019 20:06:09 CEST | Business Wire | Press release

Share
Gaming Visionary Robert “Bob” Luciano’s $55 Million Mohawk Valley Retreat to Auction via Concierge Auctions

A 16,350-square-foot property in Graeagle, CA – owned by gaming visionary Robert “Bob” Luciano, a leading figure in casino technology innovation – will auction next month via leading global firm Concierge Auctions. Known as “The Cedars,” the property features Cedars Lodge, the 16,000+-square-foot main residence, a 5,500-square-foot guest bunkhouse, a Carriage guesthouse, five-stall stable with apartment, small arena, an entertainment pavilion, two wine caves, and a large workshop with office. 1245 Carmichael Road will sell Without Reserve in cooperation with Trinkie Watson of Chase International. Bidding, which will be held via Concierge Auctions’ online marketplace, will open on July 16th and close on July 19th .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005428/en/

“This auction presents a rare opportunity for a casual to luxury lifestyle,” said Watson. “The one-of-a-kind property offers rare amenities and endless potential for a variety of luxury home buyers.”

Previously listed for $55 million, the main residence of this property, Cedar Lodge, is comprised of 16,350 square feet with three floors and includes covered patios, scenic views from large windows, and a state-of-the-art centralized and zone lighting system. There are four total bedroom suites; two on the top floor that each have a fireplace, sitting area and covered balcony, and two on the lower level, each with kitchenettes and one with a fireplace. The main level boasts a grand hall, piano stage, several seating and dining areas, large commercial kitchen, service and main elevators, recreation room, and a full indoor/outdoor bar. Architectural features include copper roofing, solid wood paneling of reclaimed Douglas fir, clear and knotty solid cedar, and clear mahogany.

The carriage house of the property is a studio above a two-car garage with rustic craftsman architecture. The 768-square-foot space provides geothermal, hydronic heat. The bunk house, which is two stories with a large area for wine/cider making, is a total of 5,512 square feet with a living area and shop level. The suggested use for this space is wine making with a 120/240 power and loading dock. Additionally, the property has five ponds landscaped with Yuba rock.

The estate is conveniently located near a hangar for a private jet at Nervino Aiport, which is 20 minutes away.

For more information, visit ConciergeAuctions.com  or call +1.212.202.2940.

Contact:

Kari Neering kari@relevanceinternational.com Ethan Elkins ethan@relevanceinternational.com (212) 257-1500

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye